Drug Patents owned by Sage Therap

1. List of Zulresso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7635773 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9200088 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9750822 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US8410077 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US10117951 SAGE THERAP Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US10322139 SAGE THERAP Neuroactive steroid formulations and methods of treating CNS disorders
Jan, 2033

(9 years from now)

US10251894 SAGE THERAP Anticonvulsant activity of steroids
Nov, 2033

(10 years from now)

US10940156 SAGE THERAP Neuroactive steroids, compositions, and uses thereof
Mar, 2037

(14 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 17, 2024
New Patient Population (NPP) Jun 16, 2025

Drugs and Companies using BREXANOLONE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 17 June, 2019

Treatment: Method of treating postpartum depression

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in